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From the Department of Neurology, University Hospital Zurich, Switzerland
Bogdahn U, Hau P, Stockhammer G, et al.; Trabedersen
Glioma Study Group. Targeted therapy for high-grade
glioma with the TGF-β2 inhibitor Trabedersen: results of a
randomized and controlled phase IIb study. Neuro Oncol
2011; 13: 132–42.
In the January issue, the results of the randomized phase-IIb
study on an antisense oligonucleotide against transforming
growth factor (TGF) β2, Trabedersen, were presented. This
study was the first randomized study to assess the safety and
efficacy of a TGFβ-antagonistic approach in glioblastoma.
Although the trial was negative for the primary endpoint, the
investigators provided extensive subgroup analyses to support
the claim that Trabedersen was active in patients with recur-
rent anaplastic astrocytoma and subgroups of patients with
glioblastoma. These interpretations raised concerns as sum-
marized in the correspondence section of the May issue of the
journal.
→ Chamberlain MC. Convection-enhanced delivery of a
transforming growth factor-{beta}2 inhibitor Trabedersen
for recurrent high-grade gliomas: efficacy real or imag-
ined?, in reference to Bogdahn et al. (Neuro-Oncology
2011; 13: 132–42). Neuro Oncol 2011; 13: 558–9.
→ Wick W, Weller M. Trabedersen to target transforming
growth factor-{beta}: when the journey is not the reward,
in reference to Bogdahn et al. (Neuro-Oncology 2011; 13:
132–42). Neuro Oncol 2011; 13: 559–60.
→ Bogdahn U. Response to MC Chamberlain: Convection-
enhanced delivery of transforming growth factor-{beta}2
inhibitor Trabedersen for recurrent high-grade gliomas:
efficacy real or imagined?, in reference to W Wick and M
Weller: Trabedersen to target transforming growth factor-
{beta}: when the journey is not the reward, in reference to
Bogdahn et al. (Neuro-Oncology 2011; 13: 132–42).
Neuro Oncol 2011; 13: 561–2.
Reardon DA, Galanis E, DeGroot JF, et al. Clinical trial end
points for high-grade glioma: the evolving landscape. Neuro
Oncol 2011; 13: 353–61.
In the March issue, the Response Assessment in Neuro-Oncol-
ogy (RANO) Working Group published a position paper on
the currently used clinical trial endpoints in the field of malig-
nant glioma, including a critical reappraisal of radiographic
endpoints, the associated limitations of progression-free sur-
vival as an endpoint, as well as the ultimate need for demon-
strating survival benefits in this disease. This article provides
an up-to-date summary that should be valued by neurooncol-
ogists embarking on the design of clinical trials in the future.
Scott JG, Suh JH, Elson P, et al. Aggressive treatment is
appropriate for glioblastoma multiforme patients 70 years
old or older: a retrospective review of 206 cases. Neuro
Oncol 2011; 13: 428–36.
In the April issue, a retrospective review of 206 patients with
glioblastoma aged 70 or more was presented. Although the
authors concluded that aggressive treatment may be appropri-
ate in this patient population, this publication, like many others
in that area, suffers from the fact that treatment allocation was
probably heavily influenced by patient characteristics and
that less fit patients were less likely to receive what is nowa-
days considered aggressive treatment. Accordingly, only the
results from large randomized trials will eventually clarify the
role of intensifying treatment in elderly patients with glioblas-
toma.
→ Weller M, Wick W. Are we ready to demystify age in glio-
blastoma? Or does older age matter in glioblastoma?
Neuro Oncol 2011; 13: 365–6.
Johnson DR, Kimmel DW, Burch PA, et al. Phase II study of
subcutaneous octreotide in adults with recurrent or progres-
sive meningioma and meningeal hemangiopericytoma.
Neuro Oncol 2011; 13: 530–5.
In the May issue, results from a phase-II study of subcutane-
ous octreotide in patients with recurrent progressive menin-
gioma and haemangiopericytoma were reported. Treatment
with somatostatin agonists is currently among the most prom-
ising options for patients with meningioma who may not have
further surgical or radiotherapeutic options. Somewhat unex-
pectedly, no neuroradiographic responses were observed in
this group of 12 patients, with only 2 patients experiencing
prolonged progression-free survival. The search for more
effective medical treatments for meningioma must go on.
Wefel JS, Cloughesy T, Zazzali JL, et al. Neurocognitive
function in patients with recurrent glioblastoma treated with
bevacizumab. Neuro Oncol 2011; 13: 660–8.
In the June issue, Wefel et al described the neurocognitive
function in patients treated with bevacizumab in the BRAIN
trial for recurrent glioblastoma. Apparently, patients consid-
ered stable by radiographic analysis had improved or stable
neurocognitive function, indicating that the radiographic re-
sponses translated into a clinical benefit. This publication
adds to the increasing awareness that neurocognitive function
should be seriously considered at least as a surrogate endpoint
of neurooncological trials with poor-prognosis patient popu-
lations like patients with recurrent glioblastoma.
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